Insulin glargine is under clinical development by Lannett and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Insulin glargine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Insulin glargine overview

Insulin glargine is a recombinant insulin, acts as anti-diabetic agent. It is formulated as solution for subcutaneous route of administration. Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Insulin glargine biosimilar is under development for the treatment of type 1 and type 2 diabetes. The drug candidate is a long acting insulin administered by subcutaneous route in the form of solution. It acts by targeting insulin receptor.

Lannett overview

Lannett develops, manufactures, packages, markets, and distributes generic brand pharmaceutical products in tablet, capsule, and oral liquid forms. The company provides generic pharmaceuticals for medical indications such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious diseases, migraine, respiratory, urinary, and others. Lannett also offers laboratory services, product formulation, and development services, and packaging solid dosage forms. The company sells pharmaceutical products across the US to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private-label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, and health maintenance organizations. Lannett is headquartered in Trevose, Pennsylvania, the US.

For a complete picture of Insulin glargine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.